If you have been reading about certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
| Property | Value | Notes |
|---|---|---|
| Storage form | Lyophilized powder | Longer stability at -20 °C |
| Reconstitution solvent | Sterile water or buffer | Depends on intended application |
| Purity assessment | Reverse-phase HPLC | Reported as peak area percentage |
| Identity confirmation | Mass spectrometry | Compared against theoretical mass |
| Main stability concern | Repeated freeze-thaw | May promote aggregation |
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
For services to Broadcasting and to Charity. Jacqueline Blake. Lately Chair, LACA, The Food People. For services to Education. Christopher John Blandford. President, World Heritage UK. For services to World Heritage. Heather Jane Boardman. Adviser, British Fashion Council and Founder, British Beauty Council. For voluntary services to Fashion and Beauty. Professor Daniela Bortoletto. Head of Particle Physics, University of Oxford. For services to Particle Physics and to Gender Equality. Camilla Jane Bowry. Founder and Chief Executive Officer, Sal's Shoes. For services to Young People, to Education and to the Environment. Michael Andrew Boyd. Project Manager, Northern Ireland Human Rights Commission, Consultant Director for Northern Ireland, Rio Ferdinand Foundation, Chair, Belfast Healthy City and lately Director, Football Development, Irish Football Association. For services to Association Football, to Sport, to Charity and to Reconciliation in Northern Ireland. Eamonn John Boylan. Chief Executive, Greater Manchester Combined Authority. For services to Local Government. Anthony James Bravo. Principal, Basingstoke College of Technology. For services to Further Education. Dr. Stephen Brierley. Founder, Riverlane. For services to Quantum Computing. Millie Bright. Footballer. For services to Association Football. Professor Matthew Jon Brookes. Professor of Physics, University of Nottingham. For services to Physics. Abigail Margaret Brown. Councillor and lately Leader, Stoke-on-Trent City Council, and Deputy Chair, Local Government Association. For services to Local Government.
== Unrelated words in -omics == The word "comic" does not use the "omics" suffix; it derives from Greek "κωμ(ο)-" (merriment) + "-ικ(ο)-" (an adjectival suffix), rather than presenting a truncation of "σωμ(ατ)-". Similarly, the word "economy" is assembled from Greek "οικ(ο)-" (household) + "νομ(ο)-" (law or custom), and "economic(s)" from "οικ(ο)-" + "νομ(ο)-" + "-ικ(ο)-". The suffix -omics is sometimes used to create names for schools of economics, such as Reaganomics.
Genetic predisposition to substance use and a history of substance use increase the risk of persistent discontinuation syndrome symptoms. Treatment for physical withdrawal generally involves switching the patient to a long-acting benzodiazepine such as diazepam or clonazepam, then slowly titrating them off the replacement drug completely at a rate that is both reasonably comfortable for the patient but rapid enough for the managing physician to consider the rate of progress acceptable (overly rapid dose reduction greatly increases the risk of patient non-compliance, such as the use of illicitly obtained alternative sedatives and/or alcohol). Psychotherapy and cognitive behavioral therapy have demonstrated moderate success in reducing the rebound anxiety that results upon carisoprodol discontinuation but only when combined with regular and active attendance to a substance use support group. Carisoprodol withdrawal can be life-threatening (especially in high-dose users and those who attempt to quit "cold turkey"). Medical supervision is recommended, with gradual reduction of dose or a substitute medication, as with other depressant drugs.
Brine pockets which are accessed by smaller pores can experience a higher abundance of photoautotrophic protists as well as smaller heterotrophic protists due to limited grazing pressure by the reduced abundance of large predators, such as large ciliates and metazoan predators.
Sources: en.wikipedia.org
== Early life and education == Young grew up in southern Los Angeles, between Compton and Lynwood. He was raised by his great-grandparents. He spent most days at church, where he played drums for the choir. Channel left home to study music at Oral Roberts University, a private Christian university in Tulsa, Oklahoma.
Bigga (Jamaica) Tropical Crema Soda (El Salvador) DG Soft Drink Cream Soda (Jamaica) Colombiana (Colombia) Kola Román (Colombia) Frescolita (Venezuela) – a bubble gum-flavored soda Kola Dumbo (Venezuela) – a bubble gum-flavored soda Grapette (Venezuela) – a bubble gum-flavored soda Marbel (Venezuela) – a bubble gum-flavored soda Inca Kola (Peru) – sometimes considered a champagne cola, sometimes considered its own drink Old Jamaica Cream Soda (Jamaica) Solo Beverage Company (Trinidad) ToniCol (Mexico) – a naturally flavored vanilla soda
=== Mating === Males attract females by singing via stridulation. An interested female will respond singing a similar-sounding song. The male will respond to the female by singing again. This can continue until copulation or the female becomes disinterested. Although a female response to male song does not guarantee mating it does increase the likelihood of copulation. Upon contact the male will produce a soft song and mount the female.
=== Reservations by individual countries === When joining any of the three drug treaties, a country has the option to make reservations in order to modify or exclude specific treaty provisions for that country. In joining the 1971 Convention on Psychotropic Substances, the US filed a reservation excepting "peyote harvested and distributed for use by the Native American Church in its religious rites"; the American Drug Enforcement Administration (DEA) made a corresponding exemption to the US Controlled Substances Act. In January 2012, Bolivia withdrew from the Single Convention over the indigenous use of the coca leaf. It soon re-applied to the convention with a reservation allowing traditional use of coca; the re-accession came into force in February 2013. Blocking the reservation required objection by 61 countries, one-third of the, at the time, 183 parties to the convention; 15 countries objected by the deadline. The UNODC said it would "continue to work in Bolivia in accordance with its mandates to support the national system of drug control and the country's international cooperation in these matters."
== Notable environmental chemists == Joan Berkowitz Paul Crutzen (Nobel Prize in Chemistry, 1995) Philip Gschwend Alice Hamilton John M. Hayes Charles David Keeling Ralph Keeling Mario Molina (Nobel Prize in Chemistry, 1995) James J. Morgan Clair Patterson Roger Revelle Sherry Roland (Nobel Prize in Chemistry, 1995) Robert Angus Smith Susan Solomon Werner Stumm Ellen Swallow Richards Hans Suess John Tyndall
Sources: en.wikipedia.org
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.
Reverse-phase HPLC separates components by hydrophobicity and reports purity as a percentage of total peak area. It does not by itself confirm molecular identity. Mass spectrometry is used alongside it for that purpose.
They link a specific lot to its analytical results and storage history. This traceability supports reproducibility when results differ between experiments. Records also help identify when re-testing is warranted.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.